カテゴリ： GlobalInfoResearch, 世界, 医療/バイオ

世界のA型肝炎及びB型肝炎用混合ワクチン市場2022年：市場規模予測（～2028年）

■ 英語タイトル：Global Hepatitis A and B Combined Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028

調査会社GlobalInfoResearch社が発行したリサーチレポート（データ管理コード：GIR22NO19374）■ 発行会社/調査会社：GlobalInfoResearch
■ 商品コード：GIR22NO19374
■ 発行日：2022年11月（※2025年版があります。お問い合わせください。）
■ 調査対象地域：グローバル
■ 産業分野：医薬品
■ ページ数：71
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（注文後2-3日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,480 ⇒換算￥528,960見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,220 ⇒換算￥793,440見積依頼/購入/質問フォーム
Corporate User（同一法人内共有可）USD6,960 ⇒換算￥1,057,920見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※GlobalInfoResearch社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[世界のA型肝炎及びB型肝炎用混合ワクチン市場2022年：市場規模予測（～2028年）]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

A型肝炎及びB型肝炎用混合ワクチン市場レポートは、世界の市場規模、地域および国レベルの市場規模、セグメント市場の成長性、市場シェア、競争環境、販売分析、国内および世界の市場プレーヤーの影響、バリューチェーンの最適化、最近の動向、機会分析、市場成長の戦略的な分析、製品発売、地域市場の拡大などに関する情報を提供します。
GlobalInfoResearchの最新の調査によると、世界のA型肝炎及びB型肝炎用混合ワクチンの市場規模は2021年のxxx米ドルから2028年にはxxx米ドルと推定され、xxx％の成長率で成長すると予想されます。

A型肝炎及びB型肝炎用混合ワクチン市場は種類と用途によって区分されます。2017年～2028年において、量と金額の観点から種類別および用途別セグメントの売上予測データを提供します。この分析は、適格なニッチ市場をターゲットにすることでビジネスを拡大するのに役立ちます。

種類別セグメントは次をカバーします。
・生ウイルスあり、生ウイルスなし

用途別セグメントは次のように区分されます。
・子供、大人

世界のA型肝炎及びB型肝炎用混合ワクチン市場の主要な市場プレーヤーは以下のとおりです。
・GSK、Sinovac

地域別セグメントは次の地域・国をカバーします。
・北米（米国、カナダ、メキシコ）
・ヨーロッパ（ドイツ、フランス、イギリス、ロシア、イタリア）
・アジア太平洋（日本、中国、韓国、インド、東南アジア、オーストラリア）
・南アメリカ（ブラジル、アルゼンチン、コロンビア）
・中東およびアフリカ（サウジアラビア、UAE、エジプト、南アフリカ）

本調査レポートの内容は計15章あります。
・第1章では、A型肝炎及びB型肝炎用混合ワクチン製品の調査範囲、市場の概要、市場の成長要因・阻害要因、および市場動向について説明します。
・第2章では、主要なA型肝炎及びB型肝炎用混合ワクチンメーカーの企業概要、2019年～2022年までのA型肝炎及びB型肝炎用混合ワクチンの価格、販売量、売上、市場シェアを掲載しています。
・第3章では、主要なA型肝炎及びB型肝炎用混合ワクチンメーカーの競争状況、販売量、売上、世界市場シェアが重点的に比較分析されています。
・第4章では、2017年～2028年までの地域別A型肝炎及びB型肝炎用混合ワクチンの販売量、売上、成長性を示しています。
・第5、6章では、2017年～2028年までのA型肝炎及びB型肝炎用混合ワクチンの種類別と用途別の市場規模、市場シェアと成長率を掲載しています。
・第7、8、9、10、11章では、2017年～2022年までの世界の主要国での販売量、売上、市場シェア、並びに2023年～2028年までの主要地域でのA型肝炎及びB型肝炎用混合ワクチン市場予測を収録しています。
・第12章では、主要な原材料、主要なサプライヤー、およびA型肝炎及びB型肝炎用混合ワクチンの産業チェーンを掲載しています。
・第13、14、15章では、A型肝炎及びB型肝炎用混合ワクチンの販売チャネル、販売業者、顧客、調査結果と結論、付録、データソースなどについて説明します。

***** 目次(一部) *****

・市場概要
- A型肝炎及びB型肝炎用混合ワクチンの概要
- 種類別分析（2017年vs2021年vs2028年）：生ウイルスあり、生ウイルスなし
- 用途別分析（2017年vs2021年vs2028年）：子供、大人
- 世界のA型肝炎及びB型肝炎用混合ワクチン市場規模・予測
- 世界のA型肝炎及びB型肝炎用混合ワクチン生産能力分析
- 市場の成長要因・阻害要因・動向
・メーカー情報（企業概要、製品概要、販売量、価格、売上）
- GSK、Sinovac
・メーカー別市場シェア・市場集中度
・地域別市場分析2017年-2028年
・種類別分析2017年-2028年：生ウイルスあり、生ウイルスなし
・用途別分析2017年-2028年：子供、大人
・A型肝炎及びB型肝炎用混合ワクチンの北米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：アメリカ、カナダ、メキシコなど
・A型肝炎及びB型肝炎用混合ワクチンのヨーロッパ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ドイツ、イギリス、フランス、ロシア、イタリアなど
・A型肝炎及びB型肝炎用混合ワクチンのアジア市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：中国、日本、韓国、インド、東南アジア、オーストラリアなど
・A型肝炎及びB型肝炎用混合ワクチンの南米市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：ブラジル、アルゼンチンなど
・A型肝炎及びB型肝炎用混合ワクチンの中東・アフリカ市場
- 種類別市場規模2017年-2028年
- 用途別市場規模2017年-2028年
- 主要国別市場規模：サウジアラビア、トルコ、エジプト、南アフリカなど
・原材料および産業チェーン
・販売チャネル、流通業者・代理店、顧客リスト
・調査の結果・結論

The Hepatitis A and B Combined Vaccine market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Hepatitis A and B Combined Vaccine market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Children accounting for % of the Hepatitis A and B Combined Vaccine global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While With Live Virus segment is altered to a % CAGR between 2022 and 2028.
Global key manufacturers of Hepatitis A and B Combined Vaccine include GSK, Sinovac, , , and , etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Hepatitis A and B Combined Vaccine market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
With Live Virus
Without Live Virus
Market segment by Application can be divided into
Children
Adult
The key market players for global Hepatitis A and B Combined Vaccine market are listed below:
GSK
Sinovac
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Hepatitis A and B Combined Vaccine product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Hepatitis A and B Combined Vaccine, with price, sales, revenue and global market share of Hepatitis A and B Combined Vaccine from 2019 to 2022.
Chapter 3, the Hepatitis A and B Combined Vaccine competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Hepatitis A and B Combined Vaccine breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2017 to 2028.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2017 to 2022.and Hepatitis A and B Combined Vaccine market forecast, by regions, type and application, with sales and revenue, from 2023 to 2028.
Chapter 12, the key raw materials and key suppliers, and industry chain of Hepatitis A and B Combined Vaccine.
Chapter 13, 14, and 15, to describe Hepatitis A and B Combined Vaccine sales channel, distributors, customers, research findings and conclusion, appendix and data source.

*** レポート目次（コンテンツ）***

1 Market Overview
1.1 Hepatitis A and B Combined Vaccine Introduction
1.2 Market Analysis by Type
1.2.1 Overview: Global Hepatitis A and B Combined Vaccine Revenue by Type: 2017 Versus 2021 Versus 2028
1.2.2 With Live Virus
1.2.3 Without Live Virus
1.3 Market Analysis by Application
1.3.1 Overview: Global Hepatitis A and B Combined Vaccine Revenue by Application: 2017 Versus 2021 Versus 2028
1.3.2 Children
1.3.3 Adult
1.4 Global Hepatitis A and B Combined Vaccine Market Size & Forecast
1.4.1 Global Hepatitis A and B Combined Vaccine Sales in Value (2017 & 2021 & 2028)
1.4.2 Global Hepatitis A and B Combined Vaccine Sales in Volume (2017-2028)
1.4.3 Global Hepatitis A and B Combined Vaccine Price (2017-2028)
1.5 Global Hepatitis A and B Combined Vaccine Production Capacity Analysis
1.5.1 Global Hepatitis A and B Combined Vaccine Total Production Capacity (2017-2028)
1.5.2 Global Hepatitis A and B Combined Vaccine Production Capacity by Geographic Region
1.6 Market Drivers, Restraints and Trends
1.6.1 Hepatitis A and B Combined Vaccine Market Drivers
1.6.2 Hepatitis A and B Combined Vaccine Market Restraints
1.6.3 Hepatitis A and B Combined Vaccine Trends Analysis
2 Manufacturers Profiles
2.1 GSK
2.1.1 GSK Details
2.1.2 GSK Major Business
2.1.3 GSK Hepatitis A and B Combined Vaccine Product and Services
2.1.4 GSK Hepatitis A and B Combined Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2 Sinovac
2.2.1 Sinovac Details
2.2.2 Sinovac Major Business
2.2.3 Sinovac Hepatitis A and B Combined Vaccine Product and Services
2.2.4 Sinovac Hepatitis A and B Combined Vaccine Sales, Price, Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
3 Hepatitis A and B Combined Vaccine Breakdown Data by Manufacturer
3.1 Global Hepatitis A and B Combined Vaccine Sales in Volume by Manufacturer (2019, 2020, 2021, and 2022)
3.2 Global Hepatitis A and B Combined Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022)
3.3 Key Manufacturer Market Position in Hepatitis A and B Combined Vaccine
3.4 Market Concentration Rate
3.4.1 Top 3 Hepatitis A and B Combined Vaccine Manufacturer Market Share in 2021
3.4.2 Top 6 Hepatitis A and B Combined Vaccine Manufacturer Market Share in 2021
3.5 Global Hepatitis A and B Combined Vaccine Production Capacity by Company: 2021 VS 2022
3.6 Manufacturer by Geography: Head Office and Hepatitis A and B Combined Vaccine Production Site
3.7 New Entrant and Capacity Expansion Plans
3.8 Mergers & Acquisitions
4 Market Analysis by Region
4.1 Global Hepatitis A and B Combined Vaccine Market Size by Region
4.1.1 Global Hepatitis A and B Combined Vaccine Sales in Volume by Region (2017-2028)
4.1.2 Global Hepatitis A and B Combined Vaccine Revenue by Region (2017-2028)
4.2 North America Hepatitis A and B Combined Vaccine Revenue (2017-2028)
4.3 Europe Hepatitis A and B Combined Vaccine Revenue (2017-2028)
4.4 Asia-Pacific Hepatitis A and B Combined Vaccine Revenue (2017-2028)
4.5 South America Hepatitis A and B Combined Vaccine Revenue (2017-2028)
4.6 Middle East and Africa Hepatitis A and B Combined Vaccine Revenue (2017-2028)
5 Market Segment by Type
5.1 Global Hepatitis A and B Combined Vaccine Sales in Volume by Type (2017-2028)
5.2 Global Hepatitis A and B Combined Vaccine Revenue by Type (2017-2028)
5.3 Global Hepatitis A and B Combined Vaccine Price by Type (2017-2028)
6 Market Segment by Application
6.1 Global Hepatitis A and B Combined Vaccine Sales in Volume by Application (2017-2028)
6.2 Global Hepatitis A and B Combined Vaccine Revenue by Application (2017-2028)
6.3 Global Hepatitis A and B Combined Vaccine Price by Application (2017-2028)
7 North America by Country, by Type, and by Application
7.1 North America Hepatitis A and B Combined Vaccine Sales by Type (2017-2028)
7.2 North America Hepatitis A and B Combined Vaccine Sales by Application (2017-2028)
7.3 North America Hepatitis A and B Combined Vaccine Market Size by Country
7.3.1 North America Hepatitis A and B Combined Vaccine Sales in Volume by Country (2017-2028)
7.3.2 North America Hepatitis A and B Combined Vaccine Revenue by Country (2017-2028)
7.3.3 United States Market Size and Forecast (2017-2028)
7.3.4 Canada Market Size and Forecast (2017-2028)
7.3.5 Mexico Market Size and Forecast (2017-2028)
8 Europe by Country, by Type, and by Application
8.1 Europe Hepatitis A and B Combined Vaccine Sales by Type (2017-2028)
8.2 Europe Hepatitis A and B Combined Vaccine Sales by Application (2017-2028)
8.3 Europe Hepatitis A and B Combined Vaccine Market Size by Country
8.3.1 Europe Hepatitis A and B Combined Vaccine Sales in Volume by Country (2017-2028)
8.3.2 Europe Hepatitis A and B Combined Vaccine Revenue by Country (2017-2028)
8.3.3 Germany Market Size and Forecast (2017-2028)
8.3.4 France Market Size and Forecast (2017-2028)
8.3.5 United Kingdom Market Size and Forecast (2017-2028)
8.3.6 Russia Market Size and Forecast (2017-2028)
8.3.7 Italy Market Size and Forecast (2017-2028)
9 Asia-Pacific by Region, by Type, and by Application
9.1 Asia-Pacific Hepatitis A and B Combined Vaccine Sales by Type (2017-2028)
9.2 Asia-Pacific Hepatitis A and B Combined Vaccine Sales by Application (2017-2028)
9.3 Asia-Pacific Hepatitis A and B Combined Vaccine Market Size by Region
9.3.1 Asia-Pacific Hepatitis A and B Combined Vaccine Sales in Volume by Region (2017-2028)
9.3.2 Asia-Pacific Hepatitis A and B Combined Vaccine Revenue by Region (2017-2028)
9.3.3 China Market Size and Forecast (2017-2028)
9.3.4 Japan Market Size and Forecast (2017-2028)
9.3.5 Korea Market Size and Forecast (2017-2028)
9.3.6 India Market Size and Forecast (2017-2028)
9.3.7 Southeast Asia Market Size and Forecast (2017-2028)
9.3.8 Australia Market Size and Forecast (2017-2028)
10 South America by Region, by Type, and by Application
10.1 South America Hepatitis A and B Combined Vaccine Sales by Type (2017-2028)
10.2 South America Hepatitis A and B Combined Vaccine Sales by Application (2017-2028)
10.3 South America Hepatitis A and B Combined Vaccine Market Size by Country
10.3.1 South America Hepatitis A and B Combined Vaccine Sales in Volume by Country (2017-2028)
10.3.2 South America Hepatitis A and B Combined Vaccine Revenue by Country (2017-2028)
10.3.3 Brazil Market Size and Forecast (2017-2028)
10.3.4 Argentina Market Size and Forecast (2017-2028)
11 Middle East & Africa by Country, by Type, and by Application
11.1 Middle East & Africa Hepatitis A and B Combined Vaccine Sales by Type (2017-2028)
11.2 Middle East & Africa Hepatitis A and B Combined Vaccine Sales by Application (2017-2028)
11.3 Middle East & Africa Hepatitis A and B Combined Vaccine Market Size by Country
11.3.1 Middle East & Africa Hepatitis A and B Combined Vaccine Sales in Volume by Country (2017-2028)
11.3.2 Middle East & Africa Hepatitis A and B Combined Vaccine Revenue by Country (2017-2028)
11.3.3 Turkey Market Size and Forecast (2017-2028)
11.3.4 Egypt Market Size and Forecast (2017-2028)
11.3.5 Saudi Arabia Market Size and Forecast (2017-2028)
11.3.6 South Africa Market Size and Forecast (2017-2028)
12 Raw Material and Industry Chain
12.1 Raw Material of Hepatitis A and B Combined Vaccine and Key Manufacturers
12.2 Manufacturing Costs Percentage of Hepatitis A and B Combined Vaccine
12.3 Hepatitis A and B Combined Vaccine Production Process
12.4 Hepatitis A and B Combined Vaccine Industrial Chain
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.2 Hepatitis A and B Combined Vaccine Typical Distributors
13.3 Hepatitis A and B Combined Vaccine Typical Customers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Research Process and Data Source
15.3 Disclaimer

List of Tables
Table 1. Global Hepatitis A and B Combined Vaccine Revenue by Type, (USD Million), 2017 & 2021 & 2028
Table 2. Global Hepatitis A and B Combined Vaccine Revenue by Application, (USD Million), 2017 & 2021 & 2028
Table 3. GSK Basic Information, Manufacturing Base and Competitors
Table 4. GSK Major Business
Table 5. GSK Hepatitis A and B Combined Vaccine Product and Services
Table 6. GSK Hepatitis A and B Combined Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 7. Sinovac Basic Information, Manufacturing Base and Competitors
Table 8. Sinovac Major Business
Table 9. Sinovac Hepatitis A and B Combined Vaccine Product and Services
Table 10. Sinovac Hepatitis A and B Combined Vaccine Sales (K Units), Price (US$/Unit), Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 11. Global Hepatitis A and B Combined Vaccine Sales by Manufacturer (2019, 2020, 2021, and 2022) & (K Units)
Table 12. Global Hepatitis A and B Combined Vaccine Revenue by Manufacturer (2019, 2020, 2021, and 2022) & (USD Million)
Table 13. Market Position of Manufacturers in Hepatitis A and B Combined Vaccine, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2021
Table 14. Global Hepatitis A and B Combined Vaccine Production Capacity by Company, (K Units): 2020 VS 2021
Table 15. Head Office and Hepatitis A and B Combined Vaccine Production Site of Key Manufacturer
Table 16. Hepatitis A and B Combined Vaccine New Entrant and Capacity Expansion Plans
Table 17. Hepatitis A and B Combined Vaccine Mergers & Acquisitions in the Past Five Years
Table 18. Global Hepatitis A and B Combined Vaccine Sales by Region (2017-2022) & (K Units)
Table 19. Global Hepatitis A and B Combined Vaccine Sales by Region (2023-2028) & (K Units)
Table 20. Global Hepatitis A and B Combined Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 21. Global Hepatitis A and B Combined Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 22. Global Hepatitis A and B Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 23. Global Hepatitis A and B Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 24. Global Hepatitis A and B Combined Vaccine Revenue by Type (2017-2022) & (USD Million)
Table 25. Global Hepatitis A and B Combined Vaccine Revenue by Type (2023-2028) & (USD Million)
Table 26. Global Hepatitis A and B Combined Vaccine Price by Type (2017-2022) & (US$/Unit)
Table 27. Global Hepatitis A and B Combined Vaccine Price by Type (2023-2028) & (US$/Unit)
Table 28. Global Hepatitis A and B Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 29. Global Hepatitis A and B Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 30. Global Hepatitis A and B Combined Vaccine Revenue by Application (2017-2022) & (USD Million)
Table 31. Global Hepatitis A and B Combined Vaccine Revenue by Application (2023-2028) & (USD Million)
Table 32. Global Hepatitis A and B Combined Vaccine Price by Application (2017-2022) & (US$/Unit)
Table 33. Global Hepatitis A and B Combined Vaccine Price by Application (2023-2028) & (US$/Unit)
Table 34. North America Hepatitis A and B Combined Vaccine Sales by Country (2017-2022) & (K Units)
Table 35. North America Hepatitis A and B Combined Vaccine Sales by Country (2023-2028) & (K Units)
Table 36. North America Hepatitis A and B Combined Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 37. North America Hepatitis A and B Combined Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 38. North America Hepatitis A and B Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 39. North America Hepatitis A and B Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 40. North America Hepatitis A and B Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 41. North America Hepatitis A and B Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 42. Europe Hepatitis A and B Combined Vaccine Sales by Country (2017-2022) & (K Units)
Table 43. Europe Hepatitis A and B Combined Vaccine Sales by Country (2023-2028) & (K Units)
Table 44. Europe Hepatitis A and B Combined Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 45. Europe Hepatitis A and B Combined Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 46. Europe Hepatitis A and B Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 47. Europe Hepatitis A and B Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 48. Europe Hepatitis A and B Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 49. Europe Hepatitis A and B Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 50. Asia-Pacific Hepatitis A and B Combined Vaccine Sales by Region (2017-2022) & (K Units)
Table 51. Asia-Pacific Hepatitis A and B Combined Vaccine Sales by Region (2023-2028) & (K Units)
Table 52. Asia-Pacific Hepatitis A and B Combined Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 53. Asia-Pacific Hepatitis A and B Combined Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 54. Asia-Pacific Hepatitis A and B Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 55. Asia-Pacific Hepatitis A and B Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 56. Asia-Pacific Hepatitis A and B Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 57. Asia-Pacific Hepatitis A and B Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 58. South America Hepatitis A and B Combined Vaccine Sales by Country (2017-2022) & (K Units)
Table 59. South America Hepatitis A and B Combined Vaccine Sales by Country (2023-2028) & (K Units)
Table 60. South America Hepatitis A and B Combined Vaccine Revenue by Country (2017-2022) & (USD Million)
Table 61. South America Hepatitis A and B Combined Vaccine Revenue by Country (2023-2028) & (USD Million)
Table 62. South America Hepatitis A and B Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 63. South America Hepatitis A and B Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 64. South America Hepatitis A and B Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 65. South America Hepatitis A and B Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 66. Middle East & Africa Hepatitis A and B Combined Vaccine Sales by Region (2017-2022) & (K Units)
Table 67. Middle East & Africa Hepatitis A and B Combined Vaccine Sales by Region (2023-2028) & (K Units)
Table 68. Middle East & Africa Hepatitis A and B Combined Vaccine Revenue by Region (2017-2022) & (USD Million)
Table 69. Middle East & Africa Hepatitis A and B Combined Vaccine Revenue by Region (2023-2028) & (USD Million)
Table 70. Middle East & Africa Hepatitis A and B Combined Vaccine Sales by Type (2017-2022) & (K Units)
Table 71. Middle East & Africa Hepatitis A and B Combined Vaccine Sales by Type (2023-2028) & (K Units)
Table 72. Middle East & Africa Hepatitis A and B Combined Vaccine Sales by Application (2017-2022) & (K Units)
Table 73. Middle East & Africa Hepatitis A and B Combined Vaccine Sales by Application (2023-2028) & (K Units)
Table 74. Hepatitis A and B Combined Vaccine Raw Material
Table 75. Key Manufacturers of Hepatitis A and B Combined Vaccine Raw Materials
Table 76. Direct Channel Pros & Cons
Table 77. Indirect Channel Pros & Cons
Table 78. Hepatitis A and B Combined Vaccine Typical Distributors
Table 79. Hepatitis A and B Combined Vaccine Typical Customers
List of Figures
Figure 1. Hepatitis A and B Combined Vaccine Picture
Figure 2. Global Hepatitis A and B Combined Vaccine Revenue Market Share by Type in 2021
Figure 3. With Live Virus
Figure 4. Without Live Virus
Figure 5. Global Hepatitis A and B Combined Vaccine Revenue Market Share by Application in 2021
Figure 6. Children
Figure 7. Adult
Figure 8. Global Hepatitis A and B Combined Vaccine Revenue, (USD Million) & (K Units): 2017 & 2021 & 2028
Figure 9. Global Hepatitis A and B Combined Vaccine Revenue and Forecast (2017-2028) & (USD Million)
Figure 10. Global Hepatitis A and B Combined Vaccine Sales (2017-2028) & (K Units)
Figure 11. Global Hepatitis A and B Combined Vaccine Price (2017-2028) & (US$/Unit)
Figure 12. Global Hepatitis A and B Combined Vaccine Production Capacity (2017-2028) & (K Units)
Figure 13. Global Hepatitis A and B Combined Vaccine Production Capacity by Geographic Region: 2022 VS 2028
Figure 14. Hepatitis A and B Combined Vaccine Market Drivers
Figure 15. Hepatitis A and B Combined Vaccine Market Restraints
Figure 16. Hepatitis A and B Combined Vaccine Market Trends
Figure 17. Global Hepatitis A and B Combined Vaccine Sales Market Share by Manufacturer in 2021
Figure 18. Global Hepatitis A and B Combined Vaccine Revenue Market Share by Manufacturer in 2021
Figure 19. Hepatitis A and B Combined Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2021
Figure 20. Top 3 Hepatitis A and B Combined Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 21. Top 6 Hepatitis A and B Combined Vaccine Manufacturer (Revenue) Market Share in 2021
Figure 22. Global Hepatitis A and B Combined Vaccine Sales Market Share by Region (2017-2028)
Figure 23. Global Hepatitis A and B Combined Vaccine Revenue Market Share by Region (2017-2028)
Figure 24. North America Hepatitis A and B Combined Vaccine Revenue (2017-2028) & (USD Million)
Figure 25. Europe Hepatitis A and B Combined Vaccine Revenue (2017-2028) & (USD Million)
Figure 26. Asia-Pacific Hepatitis A and B Combined Vaccine Revenue (2017-2028) & (USD Million)
Figure 27. South America Hepatitis A and B Combined Vaccine Revenue (2017-2028) & (USD Million)
Figure 28. Middle East & Africa Hepatitis A and B Combined Vaccine Revenue (2017-2028) & (USD Million)
Figure 29. Global Hepatitis A and B Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 30. Global Hepatitis A and B Combined Vaccine Revenue Market Share by Type (2017-2028)
Figure 31. Global Hepatitis A and B Combined Vaccine Price by Type (2017-2028) & (US$/Unit)
Figure 32. Global Hepatitis A and B Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 33. Global Hepatitis A and B Combined Vaccine Revenue Market Share by Application (2017-2028)
Figure 34. Global Hepatitis A and B Combined Vaccine Price by Application (2017-2028) & (US$/Unit)
Figure 35. North America Hepatitis A and B Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 36. North America Hepatitis A and B Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 37. North America Hepatitis A and B Combined Vaccine Sales Market Share by Country (2017-2028)
Figure 38. North America Hepatitis A and B Combined Vaccine Revenue Market Share by Country (2017-2028)
Figure 39. United States Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 40. Canada Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 41. Mexico Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 42. Europe Hepatitis A and B Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 43. Europe Hepatitis A and B Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 44. Europe Hepatitis A and B Combined Vaccine Sales Market Share by Country (2017-2028)
Figure 45. Europe Hepatitis A and B Combined Vaccine Revenue Market Share by Country (2017-2028)
Figure 46. Germany Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 47. France Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 48. United Kingdom Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 49. Russia Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 50. Italy Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 51. Asia-Pacific Hepatitis A and B Combined Vaccine Sales Market Share by Region (2017-2028)
Figure 52. Asia-Pacific Hepatitis A and B Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 53. Asia-Pacific Hepatitis A and B Combined Vaccine Sales Market Share by Region (2017-2028)
Figure 54. Asia-Pacific Hepatitis A and B Combined Vaccine Revenue Market Share by Region (2017-2028)
Figure 55. China Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 56. Japan Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Korea Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. India Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Southeast Asia Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 60. Australia Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 61. South America Hepatitis A and B Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 62. South America Hepatitis A and B Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 63. South America Hepatitis A and B Combined Vaccine Sales Market Share by Country (2017-2028)
Figure 64. South America Hepatitis A and B Combined Vaccine Revenue Market Share by Country (2017-2028)
Figure 65. Brazil Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Argentina Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Middle East & Africa Hepatitis A and B Combined Vaccine Sales Market Share by Type (2017-2028)
Figure 68. Middle East & Africa Hepatitis A and B Combined Vaccine Sales Market Share by Application (2017-2028)
Figure 69. Middle East & Africa Hepatitis A and B Combined Vaccine Sales Market Share by Region (2017-2028)
Figure 70. Middle East & Africa Hepatitis A and B Combined Vaccine Revenue Market Share by Region (2017-2028)
Figure 71. Turkey Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. Egypt Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. Saudi Arabia Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. South Africa Hepatitis A and B Combined Vaccine Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Manufacturing Cost Structure Analysis of Hepatitis A and B Combined Vaccine in 2021
Figure 76. Manufacturing Process Analysis of Hepatitis A and B Combined Vaccine
Figure 77. Hepatitis A and B Combined Vaccine Industrial Chain
Figure 78. Sales Channel: Direct Channel vs Indirect Channel
Figure 79. Methodology
Figure 80. Research Process and Data Source


*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 世界のB型肝炎ワクチン市場2022年：市場規模予測（～2028年）
  • 世界のA型肝炎ワクチン市場2022年：市場規模予測（～2028年）
  • 世界のA型＆B型肝炎ワクチン市場2022年：市場規模予測（～2028年）
  • 世界の肝炎ワクチン市場2022年：市場規模予測（～2028年）
  • 無細胞ジフテリア百日咳菌インフルエンザ菌B型混合ワクチンのグローバル市場展望 2023年-2029年：0.5mL用量、1.5mL用量
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(GIR22NO19374 )"世界のA型肝炎及びB型肝炎用混合ワクチン市場2022年：市場規模予測（～2028年）" (英文：Global Hepatitis A and B Combined Vaccine Market 2022 by Manufacturers, Regions, Type and Application, Forecast to 2028)はGlobalInfoResearch社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。